Beyond NMDA Receptors: A Narrative Review of Ketamine’s Rapid and Multifaceted Mechanisms in Depression Treatment
Open accessThe DOI matches its Crossref record; 224 of the 224 references it cites were found in a registry or an index.
Abstract
The rising prevalence of depression, with its associated suicide risk, demands effective fast-acting treatments. Ketamine has emerged as promising, demonstrating rapid antidepressant effects. While early studies show swift mood improvements, its precise mechanisms remain unclear. This article aims to compile and synthesize the literature on ketamine’s molecular actions. Ketamine primarily works by antagonizing NMDA receptors, reducing GABAergic inhibition, and increasing glutamate release. This enhanced glutamate activates AMPA receptors, triggering crucial downstream cascades, including BDNF-TrkB and mTOR pathways, promoting synaptic proliferation and regeneration. Moreover, neuroimaging studies have demonstrated alterations in brain networks involved in emotional regulation, including the Default Mode Network (DMN), Central Executive Network (CEN), and Salience Network (SN), which are frequently disrupted in depression. Despite the promising findings, the literature reveals significant inaccuracies and gaps in understanding the full scope of ketamine’s therapeutic potential. For instance, ketamine engages with opioid receptors, insinuating a permissive role of the opioid system in amplifying ketamine’s antidepressant effects, albeit ketamine does not operate as a direct opioid agonist. Further exploration is requisite to comprehensively ascertain its safety profile, long-term efficacy, and the impact of genetic determinants, such as BDNF polymorphisms, on treatment responsiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TrkB activation triggers ERK and mTORC1 cascades, extends protein synthesis windows, and supports dendritic spine maturation”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [56]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esketamine provides a more NMDAR-centered entry into the induction pathway described above, producing rapid clinical effects but also transient dissociation and sympathomimetic effects [45,46,47,49,52,55,56].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [56]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zolghadriha, A., Anjomshoaa, A., Jamshidi, M. R., & Taherkhani, F. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05716-0 · Cited by 35
RetractedMalhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099 · cited 1×
“It is characterized by a recurrent and chronic course and is associated with a high risk of suicidal thoughts and attempts [2–4].”
THE CATECHOLAMINE HYPOTHESIS OF AFFECTIVE DISORDERS: A REVIEW OF SUPPORTING EVIDENCE
SCHILDKRAUT, J. J. (1965) · American Journal of Psychiatry · doi:10.1176/ajp.122.5.509 · Cited by 3,492
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“This inhibitory action subsequently liberates mTOR Complex 1 (mTORC1) from its regulatory constraints. mTORC1 then phosphorylates downstream targets including p70S6K and 4E-BP1 (see Figure 3) [105,143].”
Subgenual prefrontal cortex abnormalities in mood disorders
Drevets, W. C., Price, J. L., Simpson, J. R., Todd, R. D., Reich, T., Vannier, M., & Raichle, M. E. (1997) · Nature · doi:10.1038/386824a0 · Cited by 2,693 · cited 1×
“A series of magnetic resonance imaging (MRI) studies have shown a reduction in the volume of both the PFC and hippocampus by up to about 19% in patients with MDD [78,154,155], and positron emission tomography (PET) reduced metabolism in PFC [78,156].”
Estimating the true global burden of mental illness
Vigo, D., Thornicroft, G., & Atun, R. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00505-2 · Cited by 2,494
Cross-national epidemiology of DSM-IV major depressive episode
Bromet, E., Andrade, L. H., Hwang, I., Sampson, N. A., Alonso, J., de Girolamo, G., de Graaf, R., Demyttenaere, K., Hu, C., Iwata, N., et al. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-90 · Cited by 2,221
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129
Risks of all-cause and suicide mortality in mental disorders: a meta-review
Chesney, E., Goodwin, G. M., & Fazel, S. (2014) · World Psychiatry · doi:10.1002/wps.20128 · Cited by 2,115 · cited 1×
“It is characterized by a recurrent and chronic course and is associated with a high risk of suicidal thoughts and attempts [2–4].”
Research works printed but not linked: 2
- Delgado, 2000, Depression: The case for a monoamine deficiency, J. Clin. Psychiatry, 61, 7
- Depukat, 2024, Polski standard leczenia racemiczną ketaminą pacjentów z zaburzeniami depresyjnymi opracowany przez zespół roboczy powołany przez Konsultanta Krajowegow dziedzinie psychiatrii, Psychiatr. Pol., 58, 377
Cited by
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
Metadata
- Authors
- Antos, Z., Żukow, X., Bursztynowicz, L., & Jakubów, P.
- Affiliations
- Medical University of Białystok (PL)
- Corresponding author
- Jakubów, Piotr
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-12-20
- Volume
- 25
- Issue
- 24
- Pages
- 13658
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11728282
- OpenAlex
- W4405695206
- Cited by
- 21
- References
- 224
- Citations by year
- 2026: 15 · 2025: 6
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, depression, rapid-acting antidepressants, NMDA receptor antagonism, glutamate, AMPA receptors, BDNF/TrkB signaling, mTOR signaling, synaptic plasticity, default mode network, frontoparietal network, salience network, opioid receptors, BDNF polymorphism, treatment response
- MeSH terms
- Animals, Antidepressive Agents, Brain, Depression, Humans, Ketamine, Receptors, N-Methyl-D-Aspartate, Brain-Derived Neurotrophic Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beyond NMDA Receptors: A Narrative Review of Ketamine’s Rapid and Multifaceted Mechanisms in Depression Treatment. https://app.cochat.ai/papers/10.3390/ijms252413658
- The paper
- Antos, Z., Żukow, X., Bursztynowicz, L., & Jakubów, P. (2024). Beyond NMDA Receptors: A Narrative Review of Ketamine’s Rapid and Multifaceted Mechanisms in Depression Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252413658
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.